Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1996-12-30
1998-08-18
Killos, Paul J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
A01N 4500
Patent
active
057958823
ABSTRACT:
Method of treating prostatic conditions such as prostate cancer and hyperplasia by administering 1.alpha.-hydroxyprevitamin D or activated vitamin D or a combination thereof in a sustained release form or a delayed and sustained release formulation. Both the sustained release form and the delayed, sustained release form deliver increased active vitamin D blood levels without significant risk of hypercalcemia associated with other oral dosing of vitamin D forms, to provide the beneficial effect to the diseased prostate tissue.
REFERENCES:
patent: 2216719 (1940-10-01), Boer
patent: 2434015 (1948-01-01), Rosenberg et al.
patent: 4230701 (1980-10-01), Holick et al.
patent: 4335120 (1982-06-01), Holick et al.
patent: 4391802 (1983-07-01), Suda et al.
patent: 4505906 (1985-03-01), DeLuca et al.
patent: 4539153 (1985-09-01), Vandewalle et al.
patent: 4684524 (1987-08-01), Eckenhoff et al.
patent: 4728643 (1988-03-01), Holick et al.
patent: 5013728 (1991-05-01), Grodberg
patent: 5372996 (1994-12-01), Labrie
Miller et al., "The Human Prostatic Carcinoma Cell Line LNCaP Expresses Biologically Active, Specific Receptors for 1.alpha.,25-Dihydroxyvitamin D.sub.3.sup.1," 52 Cancer Res. (1992) 515-520.
K. Lehmann, D. Dreher, "Coating of Tablets and Small Particles With Acrylic resins by fluid Bed Technology," Int. J. Pharm. Tech. & Prod. Mfr. 2(4), 31-43 (1981).
Skowronski et al., "Actions of Vitamin D.sub.3 Analogs on Human Prostate Cancer Cell Lines: Comparison with 1,25-Dihydroxyvitamin D.sub.3," 136 Endocrinology (1995) 20-26.
Skowronski et al., "Vitamin D and Prostate Cancer: 1,25 Dihydroxyvitamin D.sub.3 Receptors and Actions in Human Prostate Cancer Cell Lines," 132 Endocrinology (1993) 1952-1960.
Transactions of the Association of American Physicians, vol. XCII, 1979, pp. 54-63, M. F. Holick, S. C. McNeill, J. A. MacLaughlin, S. A. Holick, M. B. Clark and J. T. Potts, Jr., "Physiologic Implications of the Formation of Previtamin D in Skin".
Chemical Abstracts, vol. 110, No. 10, 1989, Columbus, Ohio, Abstract No. 84136v, M. Takahashi, H. Mochizuki, "Enteric-Soluble Capsule Base Composed of Poly(Ethylene Glycol) or Its Substitutes and Cellulose Acetate Phthalate or Hydroxypropyl Methyl Cellulose Phthalate".
Harrison's Principles of Internal Medicine: Part Eleven, "Disorders of Bone & Mineral Metabolism," Chapter 335, E. Braunwald et al., (eds.) McGraw-Hill, New York (1987) pp. 1860-1865.
M. L. Curtin and W. H. Okamura, J. Am. Chem. Soc., vol. 113 (1991) pp. 6958-6966.
CA 116:254522 1991.
CA 115:278633 1990.
CA 116:75862 1991.
CA 110:107718 1988.
Schwartz et al., Anticancer Res. J. (1994), 14:1077-81.
Skowronski et al., Proc. Workshop Vitamin D (1994), 9th (Vit. D), 520-521.
Miller et al., Clinical Cancer Res. (1995), 1(9): 997-1003.
Hsieh et al., Biochem. Biophys. Res. Commun. (1996), 223(1), 141-146.
Helund et al., J. Steroid Biochem. Molec. Biol. (1996), 58(3): 277-288.
CA 121:292155 (1994).
CA 123:161606 (1994).
CA 123:276705 (1995).
CA 125:49987 (1996).
CA 125:293950 (1996).
Bishop Charles W.
Knutson Joyce C.
Valliere Charles R.
Bone Care International, Inc.
Killos Paul J.
Welch Teresa J.
LandOfFree
Method of treating prostatic diseases using delayed and/or susta does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating prostatic diseases using delayed and/or susta, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating prostatic diseases using delayed and/or susta will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1114902